MetLife Investment Advisors LLC increased its holdings in shares of Inspire Medical Systems (NASDAQ:INSP) by 20.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,838 shares of the company’s stock after purchasing an additional 1,175 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Inspire Medical Systems were worth $388,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently bought and sold shares of the stock. Capital Financial Planning LLC purchased a new stake in Inspire Medical Systems in the fourth quarter worth about $27,000. FinTrust Capital Advisors LLC purchased a new stake in Inspire Medical Systems in the first quarter worth about $34,000. Marshall Wace North America L.P. bought a new position in shares of Inspire Medical Systems in the first quarter worth about $45,000. Great West Life Assurance Co. Can bought a new position in shares of Inspire Medical Systems in the fourth quarter worth about $50,000. Finally, Advisory Services Network LLC boosted its stake in shares of Inspire Medical Systems by 273.3% in the first quarter. Advisory Services Network LLC now owns 1,120 shares of the company’s stock worth $64,000 after acquiring an additional 820 shares during the period.
Shares of Inspire Medical Systems stock traded down $0.51 during trading on Thursday, reaching $68.03. The company’s stock had a trading volume of 244,840 shares, compared to its average volume of 333,003. The company has a 50-day moving average price of $60.37. Inspire Medical Systems has a 1-year low of $35.43 and a 1-year high of $69.71.
In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $52.55, for a total value of $1,313,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joyce Erony sold 191,192 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $66.98, for a total transaction of $12,806,040.16. The disclosure for this sale can be found here. Insiders have sold 583,726 shares of company stock worth $36,367,502 in the last ninety days.
INSP has been the topic of several recent analyst reports. Bank of America reiterated a “sell” rating on shares of Deutsche Bank in a report on Monday, July 8th. Zacks Investment Research upgraded Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Saturday, July 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Inspire Medical Systems has a consensus rating of “Hold” and a consensus target price of $57.20.
Inspire Medical Systems Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Read More: What is a management fee?
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.